MedTrace Logo

Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma

NCT01278940 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2016-08-15

No results posted yet for this study

Summary

PRIMARY OBJECTIVES: Determination of safety and toxicity of vaccination with patients' tumour mRNA transfected DCs .

SECONDARY OBJECTIVES:Determine immunological response to the vaccine (induction of specific T-cell response) and assessment of tumour response

Conditions

  • Malignant Melanoma

Interventions

BIOLOGICAL

Dendritic Cells (DC) malignant melanoma

The patients were assigned to intradermal or intranodal DC vaccination

PROCEDURE

IL-2

IL-2 were administrated by intranodal injection

Sponsors & Collaborators

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Steinar Aamdal, M.D PhD Prof · Oslo University Hospital - Norwegian Radium Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-03-31
Primary Completion
2006-02-28
Completion
2015-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01278940 on ClinicalTrials.gov